Luca Gianni, MD  
Director, Department of Medical Oncology  
Ospedale San Raffaele and San Raffaele Scientific Institute, Milan

Results and opportunities of Neoadjuvant trial for HER2 positive breast cancer

Dr. Gianni has designed and conducted Phase I and Phase II trials with HER2-directed therapies, imatinib, mTOR-inhibitors, PI3K-inhibitors, anti-angiogenics, agents modulating T-cell response, antivascular agents, and several other new small molecules and monoclonal antibodies.

Dr. Gianni was involved and directly contributed to the development of the HER2-directed monoclonal antibody Pertuzumab in metastatic breast cancer. He designed and chaired the neoadjuvant trial known as NeoSphere, a collaboration among the Michelangelo Breast Cancer study group and Roche/Genentech, that has established the role of the combination of Trastuzumab and Pertuzumab for dual targeting of HER2. Results from the NeoSphere study were used to design the very successful trial known as Cleopatra in HER2+ metastatic breast cancer. They also led to the first accelerated approval of a drug (Pertuzumab) by the FDA in early breast cancer. A Phase III international adjuvant trial, Aphinity is ongoing. Neosphere was the first trial that clearly illustrated that the antitumor activity and rate of pathologic complete response in HER2+ positive breast cancers undergoing therapy with HER2-directed monoclonal antibodies greatly depends on the immune mechanisms and may be enhanced by addition of drugs targeting immune check points.

FRIDAY JANUARY 22  
2:00PM  
Lorry Lokey Stem Cell Research Building  
ROOM G1161